WHAT IS INSULIN RESISTANCE, AND WHY HAS NOBODY TOLD YOU ABOUT IT?

Let me ask you something that might make you uncomfortable. You have had blood work done. Probably more than once. Your doctor reviewed it with you in roughly four minutes, told you everything “looks fine,” and sent you on your way. You went home. You felt reassured. Life continued. But here is what nobody told you: the test that would have caught the most important early warning sign of metabolic disease, the one that could have changed the entire trajectory of your health, was almost certainly never ordered. Not because your doctor doesn’t care. But because the standard of care in conventional primary care medicine in America has a blind spot so large you could drive a freight train through it. And that blind spot has a name. It is called insulin resistance.

THE THING YOUR LAST BLOOD PANEL ALMOST DEFINITELY MISSED

Here is the frustrating truth. You can have profound, clinically significant insulin resistance, the root driver of metabolic syndrome, type 2 diabetes, cardiovascular disease, fatty liver disease, hormonal disruption, cognitive decline, and accelerated aging, for ten to fifteen years before your fasting glucose ever crosses the threshold that triggers a diagnosis.Ten to fifteen years. A decade or more of silent metabolic damage.

Building. Compounding. While your annual lab report says “normal.”This is not a scare tactic. This is peer-reviewed physiology. And if you are reading this after being told your bloodwork is fine, but you carry weight around your midsection, feel fatigued after meals, can’t seem to lose fat despite effort, experience afternoon energy crashes, have elevated triglycerides, or have a family history of type 2 diabetes or heart disease, then this article is the conversation your doctor has not had with you yet. That conversation ends today.

FIRST: WHAT DOES INSULIN ACTUALLY DO?

To understand insulin resistance, you first need a clean, honest picture of what insulin actually is and why it exists. Insulin is a peptide hormone produced by the beta cells of the pancreas. Its primary job is elegantly simple: when you eat carbohydrates or protein, your blood glucose rises. The pancreas senses this rise and secretes insulin into the bloodstream. Insulin then acts as a molecular key; it travels to your body’s cells, particularly in skeletal muscle, liver, and adipose tissue, and binds to insulin receptors on their surface. When insulin binds to these receptors, it triggers a cascade of events that opens the cell’s glucose transporters (primarily GLUT4 in muscle tissue), allowing glucose to flow from the bloodstream into the cell, where it is either burned for energy or stored as glycogen. The result: blood glucose comes back down. The pancreas senses this. Insulin secretion reduces. The system returns to baseline. This is the insulin axis working perfectly. Glucose rises, insulin rises, cells open their doors, glucose enters, blood glucose normalizes, insulin falls. Clean. Efficient. Elegant. Now let’s talk about what happens when this system, through years of modern lifestyle assault, begins to break down.

THE SLOW COLLAPSE: HOW INSULIN RESISTANCE DEVELOPS

Insulin resistance does not happen overnight. It is a gradual, progressive deterioration of cellular insulin sensitivity, and understanding its development is essential to understanding why catching it early matters so profoundly.
Stage 1: Chronic Glucose Overload Begins.
The modern diet, particularly the ultra-processed, high-refined-carbohydrate, high-fructose dietary pattern that dominates American eating, creates a state of chronic glucose elevation. Meals that spike blood glucose rapidly and repeatedly, day after day, year after year, demand a corresponding chronic elevation in insulin output. The pancreas obliges. It produces more insulin. Blood glucose normalizes. Everything appears fine on a standard panel. But underneath, something important is shifting.
Stage 2: Cellular Insulin Receptor Downregulation.
When insulin receptors are chronically stimulated by persistently elevated insulin levels, they do what any overstimulated receptor system does: they downregulate. They become less responsive. The cell, in a sense, starts ignoring the knock at the door. Think of it this way. If your neighbor rang your doorbell once a week, you would answer. If they rang it fifty times a day, you would eventually stop answering. Your cells do the same thing. Chronic hyperinsulinemia , chronically elevated insulin , leads to receptor desensitization. The molecular key no longer turns the lock as efficiently.
Stage 3: Compensatory Hyperinsulinemia, The Pancreas Works Overtime.
Here is where it gets dangerous. When cells become insulin-resistant, glucose does not enter them as efficiently. Blood glucose stays elevated longer. The pancreas detects this and responds the only way it knows how: by producing even more insulin. This is compensatory hyperinsulinemia. And for a period of time, sometimes years, sometimes a decade or more, the pancreas succeeds. It pumps out enough insulin to force glucose into resistant cells and keep fasting glucose in the “normal” range. Your lab report shows a fasting glucose of 92 mg/dL. Your doctor sees “normal.” Your pancreas is running a metabolic marathon just to maintain that number.
Stage 4: The Tipping Point, Pre-Diabetes and Beyond.
Eventually, the beta cells of the pancreas, stressed by years of overwork, inflamed by excess lipid accumulation (lipotoxicity), and damaged by chronically elevated glucose (glucotoxicity), begin to fail. Compensatory insulin output can no longer keep pace with peripheral insulin resistance. Fasting glucose begins to rise. The diagnosis of pre-diabetes (100–125 mg/dL) and eventually type 2 diabetes (≥126 mg/dL) follows. But here is the critical point, and the one that should make you furious if you have been receiving standard care: by the time fasting glucose rises to diagnostic levels, you may have lost 40–60% of your functional beta-cell mass. The damage was happening for years. The opportunity for early, powerful intervention was available the whole time. But the test was never ordered.

THE DANGERS OF CHRONICALLY ELEVATED INSULIN.

Most people, when they think about metabolic disease, focus on blood glucose. High blood sugar is the villain in the story they have been told. But insulin, specifically chronically elevated insulin, is arguably more dangerous in the years before glucose rises. Here is why.

Insulin is a Growth and storage hormone. Insulin does not just move glucose into cells. It is one of the most powerful anabolic and lipogenic (fat-storing) hormones in the body.

Chronically elevated insulin sends the body a continuous signal to store, to build fat, to suppress fat-burning, and to grow tissue. In the wrong metabolic context, this is profoundly harmful. The result is progressive accumulation of visceral adipose tissue, the metabolically dangerous intra-abdominal fat we discussed earlier, which in turn worsens insulin resistance, creating a vicious, self-amplifying cycle.
Hepatic (liver) insulin resistance, which typically develops earlier than peripheral insulin resistance, drives the liver to overproduce VLDL particles, elevating triglycerides and reducing HDL. This is why elevated triglycerides and low HDL are often among the first clinical signals of insulin resistance, appearing years before glucose becomes abnormal.
Insulin acts on the kidneys to promote sodium retention and on the sympathetic nervous system to increase vascular tone. The result is metabolically driven hypertension, blood pressure elevation that will not be fully addressed by antihypertensive medication alone because the root cause remains unaddressed.
In women, hyperinsulinemia drives ovarian androgen overproduction, the central mechanism of polycystic ovarian syndrome (PCOS). In men, it suppresses SHBG (sex hormone-binding globulin), altering testosterone bioavailability. Hormonal disruption driven by insulin resistance is one of the most underappreciated consequences in both genders.
Insulin at physiologic levels has mild anti-inflammatory properties. At chronically elevated levels, it promotes NF-κB activation, a master regulator of inflammatory gene expression. The result is the low-grade, chronic systemic inflammation that accelerates atherosclerosis, impairs endothelial function, and is increasingly implicated in neurodegenerative disease, including Alzheimer’s, now sometimes referred to in research literature as “Type 3 Diabetes.”
Insulin and IGF-1 (insulin-like growth factor 1, which rises with chronic hyperinsulinemia) are potent cellular growth signals. Elevated insulin and IGF-1 are associated with increased risk of colorectal, breast, endometrial, and pancreatic cancers, a connection that receives far too little attention in preventive medicine.

HERE IS WHAT SHOULD MAKE YOU ANGRY

You are living in 2026. The science on insulin resistance has been well-established for decades. The tools to measure it accurately are inexpensive, widely available, and have been available for years. And yet the vast majority of primary care physicians in America still do not routinely test for insulin resistance. The standard annual physical includes a fasting glucose and a basic lipid panel. That is it. Fasting insulin, the single most direct measurement of insulin resistance, is not part of standard care. Why? A combination of systemic factors: time constraints, reimbursement structures that reward volume over depth, a diagnostic paradigm still built around treating disease rather than preventing it, and frankly, a system not designed for the kind of proactive, individualized medicine that catching insulin resistance early demands. The result is that millions of Americans, including, statistically, a significant proportion of people reading this in Chicago right now, are walking around with significant insulin resistance, being told their labs are fine, and progressing steadily toward preventable chronic disease. This is the gap that concierge medicine exists to close.

WHAT ARE YOU MISSING RIGHT NOW?

This is the question worth sitting with. Not hypothetically. Personally. If you have never had a fasting insulin test ordered, you have an incomplete metabolic picture. Full stop. If your triglycerides are above 100 mg/dL, not 150, not 200, but above 100, your triglyceride-to-HDL ratio deserves closer examination. This ratio is one of the most accessible, underutilized surrogate markers for insulin resistance available. If you carry weight centrally, if your waist circumference is creeping up even as your weight on the scale stays “acceptable”, visceral fat accumulation and underlying insulin resistance may already be in motion. If you feel fatigued after high-carbohydrate meals, experience mid-afternoon energy crashes, feel hungry again shortly after eating, or struggle to lose fat despite caloric discipline and exercise, these are not character flaws. They are physiological signals. They are your body’s way of telling you that its glucose and insulin regulation is under strain. These signals exist right now. While your last annual physical reported everything as normal. While nobody ordered the test that would show you what is actually happening.

HOW IS INSULIN RESISTANCE ACTUALLY MEASURED?

This is where Evolve MD’s approach diverges sharply from conventional primary care, and where the depth of assessment we provide translates directly into earlier detection and more precise intervention. The Gold Standard: Hyperinsulinemic-Euglycemic Clamp. The research gold standard for measuring insulin resistance is the hyperinsulinemic-euglycemic glucose clamp, a sophisticated technique in which insulin is infused at a fixed rate while glucose is simultaneously adjusted to maintain euglycemia (normal blood glucose). The amount of glucose required to maintain normal blood sugar in the face of fixed insulin infusion directly quantifies insulin sensitivity. The more glucose required, the more insulin sensitive the patient. In practice, this test is used almost exclusively in research settings. It is too complex, expensive, and time-consuming for clinical use. You will not encounter it at your internist’s office.HOMA-IR: The Accessible, Powerful Clinical Tool. The most clinically practical tool for assessing insulin resistance is the HOMA-IR score, Homeostatic Model Assessment of Insulin Resistance. It requires two fasting lab values: fasting glucose (mg/dL) and fasting insulin (μIU/mL).The formula: HOMA-IR = (Fasting Glucose × Fasting Insulin) ÷ 405Interpretation:

HOMA-IR < 1.0: Optimal insulin sensitivity

HOMA-IR 1.0–1.9: Early insulin resistance; intervention opportunity

HOMA-IR 2.0–2.9: Moderate insulin resistance; clinically significant

HOMA-IR ≥ 3.0: Significant insulin resistance; high metabolic risk

This test requires a single fasting blood draw. It costs very little. It provides vastly more actionable information than fasting glucose alone. And it is seldom ordered in a standard annual physical. At Evolve MD, HOMA-IR is a routine component of the comprehensive metabolic workup for every member.

Fasting Insulin: The Single Most Underutilized Test in Preventive Medicine.

Fasting insulin alone , even without calculating HOMA-IR , is profoundly informative. A fasting insulin above 10 μIU/mL warrants serious clinical attention, even when fasting glucose is normal. A fasting insulin above 15–20 μIU/mL is, in my clinical judgment, a significant finding requiring comprehensive metabolic evaluation and intervention. This single test, costing a few dollars, available at any commercial lab, is the test that can identify insulin resistance a decade before type 2 diabetes develops. It is the test most likely to give you the early warning your health deserves. It is the test most likely not ordered at your last physical. The Triglyceride-to-HDL Ratio: Your Lipid Panel’s Hidden Insulin Resistance Signal. If you have had a standard lipid panel done, you already have the data for this calculation. Simply divide your fasting triglycerides by your HDL cholesterol.

Ratio < 1.5: Suggests good insulin sensitivity

Ratio 1.5–3.0: Borderline; warrants further evaluation

Ratio > 3.0: Strong surrogate marker for insulin resistance and small dense LDL predominance

A patient with triglycerides of 160 and HDL of 40 has a ratio of 4.0, a significant signal that frequently goes undiscussed because both values, viewed in isolation, might not immediately alarm a time-pressed physician.HbA1c, Essential but Insufficient Alone. Hemoglobin A1c (glycated hemoglobin) reflects average blood glucose over the preceding 2–3 months and is an essential component of metabolic assessment. But HbA1c can remain normal well into the period when insulin resistance is already clinically significant, precisely because compensatory hyperinsulinemia is successfully keeping glucose controlled. HbA1c tells you where glucose has been averaging. It does not tell you how hard your pancreas is working to keep it there. Advanced Markers Worth Discussing with Your Evolve MD PhysicianFor a complete metabolic picture, the following add meaningful clinical depth: Uric acid (elevated uric acid is both a consequence and a driver of insulin resistance, and is associated with gout, hypertension, and cardiovascular risk) · Adiponectin (low adiponectin is an independent predictor of insulin resistance and cardiovascular disease) · hsCRP and other inflammatory markers (insulin resistance drives and is driven by systemic inflammation) · ApoB (a superior measure of atherogenic particle burden compared to standard LDL) · DEXA body composition analysis (visceral fat area correlates more powerfully with insulin resistance than BMI or scale weight)

THE EVOLVE MD DIFFERENCE: WHAT COMPREHENSIVE METABOLIC ASSESSMENT ACTUALLY LOOKS LIKE.

When a new member joins Evolve MD in Chicago, their metabolic workup is not a checkbox exercise. It is a clinical investigation. We are asking: how insulin sensitive are you right now? What is the trajectory? Are you moving toward resistance or away from it? What are the driving factors specific to your life, your dietary pattern, your sleep architecture, your stress physiology, your hormonal environment, your body composition, and your family history? And what is the earliest, most powerful point of intervention for you, specifically? That investigation takes time. It takes comprehensive lab testing. It takes a physician who is not racing to the next room. It takes the kind of relationship where you can say “I’ve been exhausted after lunch for six months” and have that symptom treated as the metabolic signal it is, not dismissed as stress or aging. That is what concierge medicine in Chicago means in practice. And that is what your metabolic health deserves.

THE WINDOW THAT WON’T STAY OPEN FOREVER

Here is the truth, delivered plainly. Insulin resistance is not a permanent, irreversible condition, especially in its early and intermediate stages. With targeted, personalized intervention, insulin sensitivity can be dramatically restored. Visceral fat can be reduced. Pancreatic beta-cell function can be preserved. The trajectory toward type 2 diabetes and cardiovascular disease can be stopped, and in many cases, reversed. But this window has a timeline. The longer insulin resistance persists unaddressed, the more beta-cell mass is lost, and beta cells do not regenerate. The more visceral fat accumulates, the more entrenched the inflammatory cascade becomes. The further dyslipidemia progresses, the more arterial damage accrues. Every year that passes without detection and intervention is a year of compounding physiological cost. The patients who achieve the most dramatic metabolic reversals in my practice are not the ones who waited until their fasting glucose hit 126. They are the ones who came in when HOMA-IR was 2.1, and triglycerides were 140, and they just felt “a bit off.” They are the ones who got ahead of it. You can be one of those people. But only if you act on this information while it is still early enough to matter most.